Merck invest €40 million boost manufacturing, distribution in Asia

Merck to invest €40 mn to boost manufacturing, distribution in Asia

11:40 AM, 22nd February 2018
Merck's Nantong pharmaceutical plant in China. Photo: Asian Scientist
Merck's Nantong pharmaceutical plant in China. Photo: Asian Scientist

DARMSTADT, GERMANY: Merck announced an additional investment of €40 million to build a robust manufacturing and distribution platform in Asia over a span of two years. This investment follows Merck’s November 2016 announcement of its €80 million life science investment in Nantong, China.

“In biopharmaceutical research, time is of the essence. Our investments in the important Asian markets of South Korea, India and China ensure that our customers have ready access to the products needed to develop new therapies and biosimilars that accelerate access to health for people everywhere,” said Udit Batra, member of the Merck executive board and CEO, life science.

Manufacturing & distribution centre in Songdo, South Korea

The rapidly growing biopharmaceutical industry in South Korea makes the country one of the key life science hubs in Asia. The push for research and for rapid, custom manufacturing capabilities mean a greater need for accessibility to pharmaceutical products and solutions for the advancement of research and innovation.

Merck’s new manufacturing and distribution centre, located in the Songdo district of Incheon, will include an infrastructure to facilitate the supply of Merck products to customers in Korea and advanced cell culture media manufacturing capabilities (imMEDIAte advantage custom media). Occupying a land area of 10,141 square meters, the new site is expected to be fully operational in Q4 2019.

New manufacturing & distribution centre in Mumbai, India

The new manufacturing and distribution centre, located in Mumbai, is expected to be completed in 2019. Occupying 10 acres, the site is more than 12,000 square meters with the added capacity to meet future growth, further improving inventory availability and reducing lead times.

Mobius single-use manufacturing in Wuxi, China

China, with a burgeoning biosimilar market, is fast becoming a biotech powerhouse. Single-use technologies provide increased flexibility and efficiency which are critical for biosimilar development and manufacturing. This investment, to accelerate Merck’s Mobius single-use manufacturing, addresses the growing biopharmaceutical demand in China. The site will be ready in 2018 and is expected to reduce lead time by at least 50 percent.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


ThyssenKrupp bags caustic soda contract from GACL-Nalco JV

MUMBAI, INDIA: ThyssenKrupp Industrial Solutions has been awarded a contract by GACL-Nalco Alkalies & Chemicals Private Limited (GNAL), for its gr ...

Read more
Kraton intents to initiate term loan reprice, maturity extension

HOUSTON, US: Kraton Corporation (KRA) and certain of its wholly-owned subsidiaries said that they intend to amend the existing senior secured ter ...

Read more
DGH may review plan to sell 60 pc stake in ONGC, Oil India fields

MUMBAI/NEW DELHI, INDIA: Directorate General of Hydrocarbons (DGH) may be rethinking its plan to sell 60 percent stake in hydrocarbon blocks held ...

Read more
Clariant re-launches innovative skin care ingredient to resist pollution effects

MUTTENZ, SWITZERLAND: Clariant International Ltd has re-launched its innovative skin defender against pollution and ageing, RedSnow, after skin explan ...

Read more
Organic acid a feed hygiene alternative for formaldehyde: Perstorp

PERSTORP, SWEDEN: Towards the end of 2017, the European Union denied the authorization of formaldehyde as a preservative and hygiene condition enhance ...

Read more
Archroma unveils new brightening agent for surface applications

REINACH, SWITZERLAND: Archroma has unveiled Leucophor MT liq, a new tetrasulfonated optical brightening agent (OBA) modified to give high whiteness pe ...

Read more